Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Core Viewpoint - Fennec Pharmaceuticals Inc. is set to release its first quarter 2025 financial results on May 13, 2025, and will host a conference call to discuss these results [1] Group 1: Financial Results Announcement - The company will announce its first quarter 2025 financial results before the U.S. financial markets open on May 13, 2025 [1] - A conference call and webcast will be held on the same day to discuss the financial and business results [1] Group 2: Conference Call & Webcast Details - The conference call is scheduled for 8:30 a.m. ET on May 13, 2025 [2] - Links for the webcast and participant registration are provided, with a recommendation to connect at least 15 minutes prior to the call [2] Group 3: Company Overview - Fennec Pharmaceuticals focuses on developing and commercializing PEDMARK, aimed at reducing platinum-induced ototoxicity in pediatric patients [3] - PEDMARK received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI [3] - The product has Orphan Drug Exclusivity in the U.S. and Pediatric Use Marketing Authorization in Europe, providing significant market protection [3]